Corcept Therapeutics Incorporated Company Profile (NASDAQ:CORT)

About Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated logoCorcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:CORT
  • CUSIP: 21835210
  • Web: www.corcept.com
Capitalization:
  • Market Cap: $1.38 billion
  • Outstanding Shares: 113,187,000
Average Prices:
  • 50 Day Moving Avg: $11.92
  • 200 Day Moving Avg: $10.16
  • 52 Week Range: $5.24 - $13.25
P/E:
  • Trailing P/E Ratio: 113.21
  • Foreward P/E Ratio: 23.46
  • P/E Growth: 0.92
Sales & Book Value:
  • Annual Revenue: $92.86 million
  • Price / Sales: 14.87
  • Book Value: $0.44 per share
  • Price / Book: 27.73
Profitability:
  • EBIDTA: $14.4 million
  • Net Margins: 13.51%
  • Return on Equity: 33.97%
  • Return on Assets: 19.04%
Debt:
  • Current Ratio: 2.59%
  • Quick Ratio: 2.48%
Misc:
  • Average Volume: 980,678 shs.
  • Beta: 2.05
  • Short Ratio: 7.42
 
Frequently Asked Questions for Corcept Therapeutics Incorporated (NASDAQ:CORT)

What is Corcept Therapeutics Incorporated's stock symbol?

Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics Incorporated's earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings data on Monday, May, 1st. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The company earned $27.60 million during the quarter, compared to the consensus estimate of $25.53 million. Corcept Therapeutics Incorporated had a return on equity of 33.97% and a net margin of 13.51%. The business's revenue was up 71.9% on a year-over-year basis. View Corcept Therapeutics Incorporated's Earnings History.

When will Corcept Therapeutics Incorporated make its next earnings announcement?

Corcept Therapeutics Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Corcept Therapeutics Incorporated.

Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?

4 brokerages have issued 12 month price targets for Corcept Therapeutics Incorporated's shares. Their predictions range from $7.00 to $20.00. On average, they anticipate Corcept Therapeutics Incorporated's stock price to reach $14.25 in the next twelve months. View Analyst Ratings for Corcept Therapeutics Incorporated.

Who are some of Corcept Therapeutics Incorporated's key competitors?

Who are Corcept Therapeutics Incorporated's key executives?

Corcept Therapeutics Incorporated's management team includes the folowing people:

  • James N. Wilson, Chairman of the Board
  • Joseph K. Belanoff M.D., President, Chief Executive Officer, Director
  • Gary Charles Robb, Chief Financial Officer, Chief Accounting Officer, Secretary
  • Renee D. Gala, Director
  • Len L. Baker Jr., Independent Director
  • Daniel Bradbury, Independent Director
  • Joseph C. Cook Jr., Independent Director
  • Patrick G. Enright, Independent Director

Who owns Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional investors include LONGITUDE CAPITAL PARTNERS, LLC (2.10%), Acadian Asset Management LLC (1.50%), Russell Investments Group Ltd. (0.54%), Capital Impact Advisors LLC (0.07%), Strs Ohio (0.06%) and Sit Investment Associates Inc. (0.06%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright and Steven Lo. View Institutional Ownership Trends for Corcept Therapeutics Incorporated.

Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC and Campbell & CO Investment Adviser LLC. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include David L Mahoney, James N Wilson, Joseph K Belanoff and Patrick G Enright. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?

Corcept Therapeutics Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Sit Investment Associates Inc., Eidelman Virant Capital, Sheets Smith Wealth Management, Bank of Montreal Can and Strs Ohio. Company insiders that have bought Corcept Therapeutics Incorporated stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics Incorporated.

How do I buy Corcept Therapeutics Incorporated stock?

Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics Incorporated's stock price today?

One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $12.20.


MarketBeat Community Rating for Corcept Therapeutics Incorporated (NASDAQ CORT)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Corcept Therapeutics Incorporated (NASDAQ:CORT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $14.25 (16.80% upside)

Analysts' Ratings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/18/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$15.00 -> $20.00LowView Rating Details
5/15/2017Piper Jaffray CompaniesSet Price TargetBuy$18.00LowView Rating Details
12/20/2016Janney Montgomery ScottInitiated CoverageSell$7.00N/AView Rating Details
11/2/2016FBR & CoSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Earnings by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Earnings History by Quarter for Corcept Therapeutics Incorporated (NASDAQ CORT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017$0.07N/AView Earnings Details
5/1/2017Q1 2017$0.03$0.04$25.53 million$27.60 millionViewListenView Earnings Details
3/6/2017Q4 2016$0.04$0.04$23.85 million$23.81 millionViewN/AView Earnings Details
11/1/2016Q316$0.01$0.02$21.24 million$21.70 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.03)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.05)$7.62 million$7.28 millionViewN/AView Earnings Details
5/7/2014Q114($0.10)($0.13)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.52 EPS

Dividends

Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 53.49%
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Institutional Ownership by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/19/2017David L MahoneyDirectorSell23,006$12.50$287,575.00View SEC Filing  
7/18/2017David L MahoneyDirectorSell6,091$12.50$76,137.50View SEC Filing  
7/13/2017David L MahoneyDirectorSell6,994$12.50$87,425.00View SEC Filing  
7/12/2017David L MahoneyDirectorSell6,510$12.50$81,375.00View SEC Filing  
5/4/2017Gary Charles RobbCFOBuy5,600$9.75$54,600.00View SEC Filing  
3/16/2017Patrick G. EnrightDirectorSell269,955$9.94$2,683,352.70View SEC Filing  
3/15/2017Patrick G EnrightDirectorSell600,000$10.15$6,090,000.00View SEC Filing  
3/8/2017Patrick G EnrightDirectorSell750,000$9.75$7,312,500.00View SEC Filing  
2/27/2017Patrick G EnrightDirectorSell2,500,000$8.81$22,025,000.00View SEC Filing  
11/25/2016Patrick G EnrightDirectorSell36,941$9.34$345,028.94View SEC Filing  
11/21/2016Patrick G EnrightDirectorSell544,100$9.56$5,201,596.00View SEC Filing  
11/16/2016Patrick G EnrightDirectorSell174,847$9.55$1,669,788.85View SEC Filing  
11/11/2016James N WilsonDirectorSell158,812$8.51$1,351,490.12View SEC Filing  
11/11/2016Joseph K BelanoffInsiderSell500,000$8.98$4,490,000.00View SEC Filing  
11/7/2016Joseph K BelanoffCEOSell500,000$8.31$4,155,000.00View SEC Filing  
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.00View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.00View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.00View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Source:
DateHeadline
nasdaq.com logoCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference ... - Nasdaq
www.nasdaq.com - July 25 at 5:22 PM
finance.yahoo.com logoCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
finance.yahoo.com - July 25 at 5:22 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) to Release Earnings on Monday
www.americanbankingnews.com - July 24 at 8:41 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Upgraded to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - July 23 at 11:50 PM
americanbankingnews.com logoDavid L. Mahoney Sells 6,091 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 21 at 7:51 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 6:50 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Director Sells $287,575.00 in Stock
www.americanbankingnews.com - July 20 at 10:24 PM
fool.com logoIs It Too Late to Get In on This Millionaire-Maker Stock?
www.fool.com - July 16 at 6:42 AM
americanbankingnews.com logoDavid L. Mahoney Sells 6,994 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 14 at 8:46 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (NASDAQ:CORT) Director David L. Mahoney Sells 6,510 Shares
www.americanbankingnews.com - July 14 at 8:46 PM
zacks.com logoCorcept Therapeutics Focuses on Korlym's Label Expansion
www.zacks.com - July 13 at 6:31 PM
finance.yahoo.com logoCorcept Therapeutics Focuses on Korlym's Label Expansion
finance.yahoo.com - July 13 at 6:30 PM
finance.yahoo.com logoETFs with exposure to Corcept Therapeutics, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 6:06 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (NASDAQ:CORT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 11 at 8:28 PM
americanbankingnews.com logoZacks Investment Research Lowers Corcept Therapeutics Incorporated (NASDAQ:CORT) to Sell
www.americanbankingnews.com - July 4 at 2:06 PM
zacks.com logoWhy is Corcept's Stock Up More Than 60% So Far This Year?
www.zacks.com - July 4 at 3:26 AM
finance.yahoo.com logoWhy is Corcept's Stock Up More Than 60% So Far This Year?
finance.yahoo.com - July 3 at 5:22 PM
finance.yahoo.com logoETFs with exposure to Corcept Therapeutics, Inc. : June 30, 2017
finance.yahoo.com - June 30 at 5:32 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 26 at 8:42 PM
fool.com logoCorcept Therapeutics Incorporated in 3 Charts - Motley Fool
www.fool.com - June 26 at 5:14 PM
fool.com logoCorcept Therapeutics Incorporated in 3 Charts
www.fool.com - June 26 at 8:47 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - June 24 at 7:58 PM
finance.yahoo.com logoETFs with exposure to Corcept Therapeutics, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:12 PM
finance.yahoo.com logoCorcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 5:13 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Lowered to Hold at BidaskClub
www.americanbankingnews.com - June 15 at 6:58 PM
finance.yahoo.com logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : June 15, 2017
finance.yahoo.com - June 15 at 6:17 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 30 at 6:34 PM
marketwatch.com logoResearch Reports Initiation on Biotech Stocks -- Corcept Therapeutics, Curis, OvaScience, and Vanda Pharma
www.marketwatch.com - May 30 at 11:59 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Upgraded at TheStreet
www.americanbankingnews.com - May 25 at 2:42 PM
finance.yahoo.com logoPharma Stock With Triple-Digit Growth Forming Blotchy Base
finance.yahoo.com - May 24 at 12:40 PM
finance.yahoo.com logoCorcept Therapeutics Incorporated (CORT)
finance.yahoo.com - May 19 at 8:37 AM
finance.yahoo.com logoETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017
finance.yahoo.com - May 18 at 4:21 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - May 15 at 2:34 PM
finance.yahoo.com logoBlog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate
finance.yahoo.com - May 12 at 4:57 PM
finance.yahoo.com logoCorcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May 10, 2017
finance.yahoo.com - May 10 at 4:36 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) CFO Gary Charles Robb Acquires 5,600 Shares
www.americanbankingnews.com - May 8 at 8:22 PM
americanbankingnews.com logoZacks Investment Research Downgrades Corcept Therapeutics Incorporated (CORT) to Hold
www.americanbankingnews.com - May 8 at 4:16 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 5 at 11:38 AM
finance.yahoo.com logoCorcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress
finance.yahoo.com - May 4 at 4:34 PM
americanbankingnews.com logoTheStreet Downgrades Corcept Therapeutics Incorporated (CORT) to C+
www.americanbankingnews.com - May 3 at 5:56 PM
finance.yahoo.com logoEdited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT
finance.yahoo.com - May 3 at 4:24 PM
finance.yahoo.com logoCorcept Therapeutics Announces First Quarter 2017 Financial ... - Yahoo Finance
finance.yahoo.com - May 3 at 8:43 AM
americanbankingnews.com logoFavorable News Coverage Somewhat Likely to Affect Corcept Therapeutics (CORT) Share Price
www.americanbankingnews.com - May 3 at 1:01 AM
finance.yahoo.com logoCorcept posts 1Q profit
finance.yahoo.com - May 2 at 7:34 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 1:03 PM
finance.yahoo.com logoInvestor Network: Corcept Therapeutics Incorporated. to Host Earnings Call
finance.yahoo.com - May 1 at 4:24 PM
finance.yahoo.com logoCorcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
finance.yahoo.com - May 1 at 4:24 PM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) Short Interest Update
www.americanbankingnews.com - April 29 at 11:56 PM
americanbankingnews.com logoCorcept Therapeutics (CORT) Receiving Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 8:28 AM
americanbankingnews.com logoCorcept Therapeutics Incorporated (CORT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:17 AM

Social

Chart

Corcept Therapeutics Incorporated (CORT) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff